Evidence map›Paper›PMID 42209818›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Comparison of [

Ran An, Yuhan Sun, Ruoxi Yang, Mengjiao Wang, Xiaoshan Chen, Xiao Pang, Jianqiang Zhao, Xiaolin Chen, Fangyu Shi, Qiang Fu and 3 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ran An *Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Yuhan Sun *Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Ruoxi YangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Mengjiao WangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Xiaoshan ChenDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Xiao PangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Jianqiang ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Xiaolin ChenDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Fangyu ShiDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Qiang FuDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Bin GuoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Jingya HanDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Xinming ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China. xinmingzhao@hebmu.edu.cn.ORCID 0000-0002-7060-2643

Funding

The Hebei Provincial Natural Science Foundation, the Jing-Jin-Ji Special Projects for Basic Research Cooperation H2018206600The Hengrui Hebei Collaborative Innovation Program in Medical Science HR202502074
6 · The paper itself

Abstract

objectiveTo evaluate early ΔSUVmax% for predicting pathological complete response (pCR) in HER2-positive breast cancer patients undergoing neoadjuvant therapy (NAT), to build a combined [

methods45 patients underwent both [

results27 of the 45 enrolled patients achieved pCR (60%). After treatment, the pCR group showed significantly lower PET/CT parameters, a significantly higher ΔSUVmax%, and significantly higher MRI-derived ADC and ΔADC% values compared to the non-pCR group. The combined PET model showed a LOOCV AUC of 0.887 (95% CI: 0.781-0.969), significantly higher than that of the combined MRI model (0.642, 95% CI: 0.474-0.803, p = 0.015). Calibration was numerically better for the PET model (p = 0.404) than for the MRI model (p = 0.309), indicating a relative advantage for PET. Decision curve analysis indicated higher clinical net benefit for the PET model across threshold probabilities of 10%-90%.

conclusionΔSUVmax% is a promising early predictor of pCR.The [

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesMagnetic Resonance ImagingNeoadjuvant TherapyPositron Emission Tomography Computed TomographyAdultAgedFemaleGallium RadioisotopesHumansMiddle AgedMolecular Targeted TherapyPathologic Complete ResponseTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGallium RadioisotopesBreast cancerMRIPET/CTTargeted neoadjuvant therapyTreatment response evaluation

Identifiers

PMID42209818

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.